argenx SE Investor Day Presentation Deck
Efgartigimod Blocks IgG Binding to FcRn Without Reducing Albumin
Mean Percent Change (+/-SE)
-20
0
4
-60
●
●
0
IgG levels - 1st cycle
argenx
60 63 63 161
2
4
61 16.3 62 13
Cycle 1
6
A
8
54
25
16
10 12
15
15
Phase 3 ADAPT Trial of Efgartigimod in Myasthenia Gravis Patients
T
16 18
Albumin (g/L)
Howard et al., The Lancet Neurology. 2021
LDL (mmol/L)
60-
50-
40-
10.0
7.5-
5.0-
2.5-
Albumin and LDL Cholesterol levels - 1st & 2nd cycles
0 1 2 3 4 5 6 7 8
0
1 2 3 4 5 6 7 8
10
10
Week
12 14 16
12
14 16
18 20
18
20
60-
50-
40-
10.0-
7.5-
5.0-
2.5-
0 1
.
3
Potent reduction in IgG levels without decrease in albumin or increase in LDL levels
No albumin decreases observed with chronic dosing out to 34 weeks in Phase 2 pemphigus trial (25mg/kg dose)
Selective blockade of IgG recycling without affecting serum albumin levels is emerging as a key differentiator in the FcRn space
Maintaining levels of human serum albumin is important for lipid housekeeping as well as other key physiological functions
4 5 6 7
.
8 10 12
0 1 2 3 4 5 6 7 8 10
Week
12
□
14 16 18 20
H
14 16 18
20
TH
T
EFGARTIGIMOD
PLACEBO
THE LANCET
Neurology
21View entire presentation